首页> 外国专利> PYRIDINO 1,2-A-DIBENZO C,F AZEPINE AND PYRIDINO 1,2-D- DIBENZO-B,F 1,4-DIAZEPINE-OXAZEPINE ORTHIAZEPINE DERIVATIVES METHODS FOR THEIR PREPARATION AND COMPOSITION CONTAINING THEM

PYRIDINO 1,2-A-DIBENZO C,F AZEPINE AND PYRIDINO 1,2-D- DIBENZO-B,F 1,4-DIAZEPINE-OXAZEPINE ORTHIAZEPINE DERIVATIVES METHODS FOR THEIR PREPARATION AND COMPOSITION CONTAINING THEM

机译:吡啶并1,2-A-二苯并C,F阿哌丁啶和吡啶并1,2-D-二苯并-B,F 1,4-二氮杂恶嗪-奥氮西庚因邻苯并ZE庚因衍生物的制备和组成方法

摘要

1471784 Fused dibenzo[c,f]azepines and dibenzo[b,f][1,4] - diazepines - oxazines and -thiazepines AKZO NV 24 April 1974 [26 April 1973] 17985/74 Heading C2C Novel compounds IV and salts thereof in which R 1 , R 2 , R 3 and R 4 are hydrogen, hydroxy, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio or trifluoromethyl, X is O, S, NR 7 or CR 8 R 9 (where R 7 is hydrogen or C 1-4 alkyl and R 8 and R 9 are each hydrogen or methyl) A is the group (where R 5 and R 6 are hydrogen, C 1-6 alkyl, C 7-10 aralkyl or NR 5 R 6 represents a 5- or 6-membered heterocyclic ring and n is 0 to 3 with the (CH 2 ) n -NR 5 R 6 moiety being either # or to the N atom) are prepared by standard methods from compounds II Compounds IV in which A is are prepared from compounds II by (1) reaction with ethylformate and sodium methoxide to give followed by tosylation, reduction and animation to give the group -CH 2 -NR 5 R 6 , (2) bromination and amination to give A= (3) Mannich reaction to give A= (4) reaction with isoamyl nitrate and potassium t-butoxide followed by reduction to give A = (5) reaction with sodamide and to give (6) reaction with hydroxylamine and tosyl chloride followed by the Nelser rearrangement to give A is Compounds IV in which A is are prepared by Wolff-Kishner reduction of the corresponding keta compounds. Compounds IV in which A is are also prepared by (1) reaction of a compound V in which Y is halogen or a sulphonyloxy group with an amine HNR 5 R 6 , (2) reduction of a compound VII in which R is -(CH 2 ) p CN or -(CH 2 ) n -N 3 (where p is 0 to 2 and n is as above) to form compounds in which R 5 and R 6 are hydrogen (3) reacting a compound II with an amine HNR 5 R 6 in the presence of a reducing agent to form compounds in which n is 0, (4) reduction of the oxime of compounds II to form compounds in which A is (5) reduction of a compound IX or X in which n is 0 to 2 to give compounds in which n#1, (6) reaction of a compound II with acetonitrile in the presence of sodium ethoxide followed by reduction to give compounds in which n = and R 5 and R 6 are hydrogen. Compounds IV in which R 5 and R 6 are hydrogen are methylated by reaction with formaldehyde. Compounds IV form isomers in which the substituent (CH 2 ) n -NR 5 R 6 may be in the equatorial or axial position. Compounds II are prepared by condensation of vinyl methyl ketone with the appropriately substituted derivative of morphanthridine, dibenzoxazepine, dibenzothiazepine or dibenzodiazepineto give the 2-oxo compound which may be converted to the 3-oxo derivative by reaction with isoamyl nitrate and potassium t-butoxide after which the 2-oxo group of the 2-oxo-3-oximino compound is reduced and the oximino moiety saponified. Compounds V are prepared by reduction of the ketone group of compounds II to hydroxy and esterifying or halogenating and for compounds V in which n is 1 to 3 extending the alkyl chain length by the standard homologation procedure. Compounds VII in which R is -(CH 2 ) n N 3 are prepared by treating a compound V with sodium azide; those in which R is -(CH 2 ) p -CN are prepared by (i) reacting a compound V (n is only 0, 1 or 2) with sodium cyanide or (ii) by reacting a compound II with HCN, eliminating the hydroxyl group and reducing the double bond. Compounds IX are prepared by hydrolysis of the cyano compounds of Formula VII to form the acid followed by conventional amidation. Compounds X are prepared by a Wittig reaction on compounds II. Compounds IV are CNS depressants and form with a carrier a pharmaceutical composition which may be administered orally or parenterally.
机译:1471784熔融的二苯并[c,f]氮杂and和二苯并[b,f] [1,4]-二氮杂--恶嗪和-噻氮pine AKZO NV 1974年4月24日[1973年4月26日] 17985/74标题C2C新颖的化合物IV及其盐其中R 1,R 2,R 3和R 4为氢,羟基,卤素,C 1-6烷基,C 1-6烷氧基,C 1-6烷硫基或三氟甲基,X为> O,> S,> NR 7或> CR 8 R 9(其中R 7为氢或C 1-4烷基,R 8和R 9各自为氢或甲基)A为基团(其中R 5和R 6为氢,C 1-6烷基,制备C 7-10芳烷基或NR 5 R 6表示5元或6元杂环,并且n为0至3,其中(CH 2)n -NR 5 R 6部分为#或N原子)由化合物II通过标准方法制备,其中化合物A是由化合物II通过以下方法制备的:(1)与甲酸乙酯和甲醇钠反应,进行甲苯磺酰化,还原和动画反应,得到基团-CH 2 -NR 5 R 6,( 2)溴化和胺化得到A =(3)曼尼希反应e A =(4)与硝酸异戊酯和叔丁醇钾反应,然后还原得到A =(5)与磺酰胺反应,与(6)与羟胺和甲苯磺酰氯反应,然后进行Nelser重排得到A为化合物其中A是通过Wolff-Kishner还原相应的Keta化合物制备的IV。还通过(1)将其中Y为卤素或磺酰氧基的化合物V与胺HNR 5 R 6反应,(2)将其中R为-(CH)的化合物VII还原来制备其中A的化合物IV。 2)p CN或-(CH 2)n -N 3(其中p为0至2且n如上)形成其中R 5和R 6为氢的化合物(3)使化合物II与胺HNR反应5 R 6在还原剂的存在下形成n为0的化合物,(4)化合物II的肟还原以形成A为的化合物(5)n为0的化合物IX或X的还原0至2得到化合物,其中化合物II与乙腈在乙醇钠存在下进行n#1,(6)反应,然后还原得到n =,R 5和R 6为氢的化合物。 R 5和R 6为氢的化合物Ⅳ通过与甲醛反应而被甲基化。化合物IV形成异构体,其中取代基(CH 2)n -NR 5 R 6可以位于赤道或轴向位置。化合物Ⅱ是通过乙烯基甲基酮与吗啡啶,二苯并x杂,二苯并噻氮杂或二苯并二氮杂卓的适当取代的衍生物缩合而制得的2-氧代化合物,该化合物可通过与硝酸异戊酯和叔丁醇钾反应后转化为3-氧代衍生物。其中2-氧代-3-氧亚氨基化合物的2-氧代基被还原并且氧亚氨基部分被皂化。化合物V是通过将化合物Ⅱ的酮基还原成羟基并酯化或卤化而制备的,对于化合物V(其中n为1至3),可通过标准的同源化方法使烷基链长延伸。通过用叠氮化钠处理化合物V来制备其中R是-(CH 2)n N 3的化合物VII。 R是-(CH 2)p -CN的化合物是通过(i)使化合物V(n仅为0、1或2)与氰化钠反应或(ii)使化合物II与HCN反应而消除的。羟基和还原双键。通过将式VII的氰基化合物水解以形成酸,然后进行常规的酰胺化反应来制备化合物IX。化合物X通过对化合物II的Wittig反应制备。化合物IV是CNS抑制剂,并与载体形成药物组合物,该药物组合物可以口服或肠胃外给药。

著录项

  • 公开/公告号GB1471784A

    专利类型

  • 公开/公告日1977-04-27

    原文格式PDF

  • 申请/专利权人 AKZO NV;

    申请/专利号GB19740017985

  • 发明设计人

    申请日1974-04-24

  • 分类号C07D487/04;A61K31/55;C07D498/04;C07D513/04;

  • 国家 GB

  • 入库时间 2022-08-22 23:41:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号